PMID- 38253245
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240226
IS  - 1532-3064 (Electronic)
IS  - 0954-6111 (Linking)
VI  - 223
DP  - 2024 Mar
TI  - Effectiveness of omalizumab across different dosing regimens in patients with 
      moderate-to-severe allergic asthma.
PG  - 107537
LID - S0954-6111(24)00011-8 [pii]
LID - 10.1016/j.rmed.2024.107537 [doi]
AB  - For patients with moderate-to-severe persistent allergic asthma, omalizumab is 
      approved for subcutaneous administration according to a recommended dosing table 
      based on weight and total immunoglobulin E (IgE) level. The aim of this analysis 
      was to assess asthma outcomes including quality of life in patients with allergic 
      asthma initiated on omalizumab in the PROSPERO trial; patients were stratified by 
      where their IgE and body weight fell on the approved dosing table. Patient groups 
      were defined as Inside Dosing Table: patients whose IgE and weight fell within 
      the approved dosing table (n = 506); Insufficient Data to Recommend a Dose: 
      patients who fell into the section of the approved dosing table where not enough 
      clinical data were available to make dosing recommendations (n = 72); and Outside 
      Dosing Table: patients who fell outside the approved dosing table due to baseline 
      IgE and/or weight (n = 209). Overall, asthma and quality of life outcomes were 
      improved after omalizumab initiation for both patients who fall within the 
      recommended dosing table or those who fall outside the recommended dosing table. 
      Our results suggest that omalizumab treatment may be effective in a wide range of 
      patients with moderate-to-severe allergic asthma. ClinicalTrials.gov identifier 
      NCT01922037.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Chase, Nicole M
AU  - Chase NM
AD  - University of Minnesota, Minneapolis, MN, USA. Electronic address: 
      nmchase@umn.edu.
FAU - Littlejohn, Monica
AU  - Littlejohn M
AD  - Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: 
      monica.d.littlejohn@vumc.org.
FAU - Holweg, Cecile T J
AU  - Holweg CTJ
AD  - Genentech, Inc., South San Francisco, CA, USA. Electronic address: 
      cholweg@gmail.com.
FAU - Millette, Lauren A
AU  - Millette LA
AD  - Genentech, Inc., South San Francisco, CA, USA. Electronic address: 
      millette.lauren@gene.com.
FAU - Seetasith, Arpamas
AU  - Seetasith A
AD  - Genentech, Inc., South San Francisco, CA, USA. Electronic address: 
      seetasia@gene.com.
FAU - Steinke, John W
AU  - Steinke JW
AD  - Genentech, Inc., South San Francisco, CA, USA. Electronic address: 
      steinke.john@gene.com.
FAU - Trzaskoma, Benjamin L
AU  - Trzaskoma BL
AD  - Genentech, Inc., South San Francisco, CA, USA. Electronic address: 
      trzaskob@gene.com.
FAU - Hanania, Nicola A
AU  - Hanania NA
AD  - Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, 
      Houston, TX, USA. Electronic address: hanania@bcm.edu.
FAU - Casale, Thomas B
AU  - Casale TB
AD  - Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA. 
      Electronic address: tbcasale@usf.edu.
LA  - eng
SI  - ClinicalTrials.gov/NCT01922037
PT  - Journal Article
DEP - 20240120
PL  - England
TA  - Respir Med
JT  - Respiratory medicine
JID - 8908438
RN  - 2P471X1Z11 (Omalizumab)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Humans
MH  - Omalizumab/therapeutic use
MH  - *Anti-Asthmatic Agents
MH  - Quality of Life
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Immunoglobulin E
MH  - *Asthma/drug therapy/chemically induced
OTO - NOTNLM
OT  - Asthma
OT  - Atopy
OT  - Immunoglobulin E
OT  - Omalizumab
OT  - Quality of life
COIS- Declaration of competing interest NMC: consultant and/or speaker bureau member 
      for Amgen, ARS Pharmaceuticals Inc., AstraZeneca, Blueprint Medicines, Bryn 
      Pharma, Genentech Inc., GlaxoSmithKline, Hikma Pharmaceuticals, Incyte, Novartis, 
      Regeneron, and Sanofi; speaker bureau member for Incyte; consultant for ARS 
      Pharmaceuticals Inc., Bryn Pharma, Genentech, Inc., Hikma Pharmaceuticals, and 
      Novartis Pharmaceuticals Corporation. ML: institution received research grant 
      support on her behalf from Sanofi; received honoraria for serving as a consultant 
      for AstraZeneca. CTJH: former employee of Genentech, Inc. LAM, AS, JWS, BLT: 
      employees of Genentech, Inc.; stockholders of Roche. NAH: received honoraria for 
      serving as advisor or consultant for Amgen, AstraZeneca, Genentech, Inc., 
      GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Regeneron, Sanofi, and 
      Teva. Institution received research grant support on his behalf from AstraZeneca, 
      Genentech, Inc., GlaxoSmithKline, Novartis, Sanofi, and Teva. TBC: consultant and 
      speaker bureau member for Genentech, Inc.; consultant for Novartis 
      Pharmaceuticals Corporation; chief medical advisor for Food Allergy Research & 
      Education.
EDAT- 2024/01/23 00:42
MHDA- 2024/02/26 06:43
CRDT- 2024/01/22 19:15
PHST- 2023/11/10 00:00 [received]
PHST- 2024/01/18 00:00 [revised]
PHST- 2024/01/19 00:00 [accepted]
PHST- 2024/02/26 06:43 [medline]
PHST- 2024/01/23 00:42 [pubmed]
PHST- 2024/01/22 19:15 [entrez]
AID - S0954-6111(24)00011-8 [pii]
AID - 10.1016/j.rmed.2024.107537 [doi]
PST - ppublish
SO  - Respir Med. 2024 Mar;223:107537. doi: 10.1016/j.rmed.2024.107537. Epub 2024 Jan 
      20.